ArticleInternational journal of cancer2009
Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results.
Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 7 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Economic Evaluation of Gastric Cancer Screening Strategies: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment ofThe Journal of international medical research · 2023Pooled it
- Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review.Journal of gastrointestinal cancer · 2022Pooled it
- Simulation Models in Gastric Cancer Screening: A Systematic ReviewAsian Pacific journal of cancer prevention : APJCP · 2018Pooled it
- Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer.The Cochrane database of systematic reviews · 2013Pooled it
- Guideline
- Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).Virchows Archiv : an international journal of pathology · 2012Guideline
- Trial
- Frequency ofCanadian liver journal · 2026Article
- The epidemiological study of family-based Helicobacter pylori screening and its benefits: a cross-sectional study.Scientific reports · 2025Article
- Article
- A Nomogram Combining Platelet to Lymphocyte Ratio (PLR) and Systemic Inflammatory Response Index (SIRI) to Predict Patients withJournal of multidisciplinary healthcare · 2025Article
- Review
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
- The Burden and Risk Factors ofResearch and reports in tropical medicine · 2024Article
- Health economic evaluation on population-basedChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- An Ultrasensitive PCR-Based CRISPR-Cas13a Method for the Detection ofJournal of personalized medicine · 2022Article
- Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Chinese Consensus Report on Family-BasedGut · 2022Article
- The role of the occupational physician in controlling gastric cancer attributable toPreventive medicine reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Gastric cancer is the second leading cause of cancer-related deaths worldwide. Treatment for Helicobacter pylori infection, the leading causal risk factor, can reduce disease progression, but the long-term impact on cancer incidence is uncertain. Using the best available data, we estimated the potential health benefits and economic consequences associated with H. pylori screening in a high-risk region of China. An empirically calibrated model of gastric cancer was used to project reduction in lifetime cancer risk, life-expectancy and costs associated with (i) single lifetime screening (age 20, 30 or 40); (ii) single lifetime screening followed by rescreening individuals with negative results and (iii) universal treatment for H. pylori (age 20, 30 or 40). Data were from the published literature and national and international databases. Screening and treatment for H. pylori at age 20 reduced the mean lifetime cancer risk by 14.5% (men) to 26.6% (women) and cost less than $1,500 per year of life saved (YLS) compared to no screening. Rescreening individuals with negative results and targeting older ages was less cost-effective. Universal treatment prevented an additional 1.5% to 2.3% of risk reduction, but incremental cost-effectiveness ratios exceeded $2,500 per YLS. Screening young adults for H. pylori could prevent one in every 4 to 6 cases of gastric cancer in China and would be considered cost-effective using the GDP per capita threshold. These results illustrate the potential promise of a gastric cancer screening program and provide rationale for urgent clinical studies to move the prevention agenda forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.